ArticleFrontiers in endocrinology2025
Allostatic load index in patients with pituitary tumours: a case control study.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- GDF15 in Patients with Autoimmune Primary Adrenal Insufficiency.International journal of molecular sciences · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Prolonged exposure to pathogenic stress factors leads to multisystemic consumption of the body and adverse changes resulting in the development of allostatic load (AL). Stress plays a crucial role in the pathophysiology of many diseases, including endocrinopathies. The purpose of our study was to evaluate the allostatic load index in patients with pituitary tumours and compare it to a control group. Materials and methods: The study group included 58 patients with hormonally active pituitary tumours and 52 patients without pituitary dysfunction, representing the control group. The AL index (ALI) was calculated based on 16 parameters grouped into the following categories: anthropometric parameters, cardiovascular markers, lipid and carbohydrate metabolism parameters, and inflammatory and hormonal markers. Results: In the group of patients with pituitary tumours, a statistically significantly higher AL index was noticed, regardless of the endocrine function of the adenoma, compared to the control group [7.00 (5.00-9.00) vs. 3.50 (2.00-5.00), p < 0.001]. Age significantly affected the AL index, while no such relationship was observed for education. Analysing specific AL biomarkers, patients with pituitary tumours had significantly higher Body Mass Index (BMI), systolic blood pressure and diastolic blood pressure. Individuals in the study group showed significantly higher levels of insulin, triglycerides and interleukin 6, and significantly lower levels of high-density lipoprotein cholesterol, dehydroepiandrosterone sulphate and albumin, compared to the control group. Conclusions: The results of our study indicate the usefulness of the AL index as an integrated tool for assessing the cumulative impact of stress factors in pituitary diseases. In addition, patients with hormonally active pituitary tumours presented a higher cardio-metabolic risk. It is necessary to analyse the clinimetric data affecting AL, which is the next step of our study.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.